Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity

详细信息    查看全文

• 作者：Alexios Matikas^a ; ^e ; Dimitrios Mistriotis^b ; Vasilios Georgoulias^d ; ^e ; Athanasios Kotsakis^c ; ^d ; ^e ; ^{kotsakis@uoc.gr}
• 关键词：KRAS ; MEK ; NSCLC ; Predictive ; Prognostic ; Targeted therapy
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：110
• 期：Complete
• 页码：1-12
• 全文大小：1518 K
• 卷排序：110

文摘

KRAS mutations are the most common genetic event in lung adenocarcinoma. The prognostic and predictive value of KRAS mutations is unclear. Previous attempts to directly target KRAS have been unsuccessful. A large number of novel agents and combinations are being currently evaluated.